How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,770 results for

Cerebral Aneurysm

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5401. A Trial of Low-dose Adjunctive alTeplase During prIMary PCI

(eGFR) <30ml/min/1.73m² previous infarction in the culprit artery (known or suspected clinically, e.g. wall motion abnormality revealed by echocardiography) Significant bleeding problem either at present or within the past 6 months Patients with current concomitant oral anticoagulant therapy (INR > 1.3), including apixaban, dabigatran and rivaroxaban Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial, or spinal surgery) Known Haemorrhagic diathesis Severe (...) haemorrhage (presence/absence); Myocardial haemorrhage extent (% of LV) Safety [ Time Frame: 2-7 days ] Acute cerebral (stroke) and systemic (GI, peripheral) bleeding (if any) with alteplase; Coagulation (fibrinogen concentration); MRI [ Time Frame: 12 weeks ] Infarct size; Myocardial salvage index (final infarct size/initial area-at-risk); LV end-diastolic volume (LVEDV); LV end-systolic volume (LVESV); LV ejection fraction (LVEF); ECG [ Time Frame: 12 weeks ] ECG for final infarct size Biochemistry

2014 Clinical Trials

5402. EXTEND Exercise Trial

or pulmonary infarction Thrombosis of lower extremities Suspected dissecting aneurysm Uncontrolled asthma Pulmonary edema Room air desaturation at rest <85% Respiratory failure Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis) Mental impairment leading to inability to cooperate. Able to swallow enzalutamide and comply with study requirements. Must be able to complete an acceptable cardiopulmonary exercise (...) ) that impairs the ability to swallow and retain enzalutamide are excluded. History of another invasive cancer within 5 years of randomization with the exceptions of (a) non-melanoma skin cancers and (b) American Joint Committee on Cancer (AJCC) Stage 0 or 1 cancers that have a remote probability of recurrence, in the opinion of the treating physician, in consultation with the principal investigator. Known or suspected brain metastasis or leptomeningeal disease. History of seizure or any condition that may

2014 Clinical Trials

5403. Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)

accident; history of stroke; TIA, cerebral aneurysm, Dementia; Parkinson's Disease; Huntington's chorea; Multiple Sclerosis. Increased risk of seizure for any reason, including prior head trauma with loss of consciousness for 5 minutes or more Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease. Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head (...) York State Psychiatric Institute Collaborator: City University of New York, School of Public Health Information provided by (Responsible Party): New York State Psychiatric Institute Study Details Study Description Go to Brief Summary: This is a randomized controlled trial (RCT) on the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of Depersonalization Disorder (DPD). TMS applies a magnetic field to the brain for a brief period of time. TMS is a procedure

2014 Clinical Trials

5404. Imaging Pain Relief in Osteoarthritis

OA knee changes with knee pain Must have self-reported knee pain Able to give informed consent Over 35 years old Male or female Females not pregnant or lactating and using effective contraception Exclusion Criteria: People with any known contraindication to MRI like Intraocular metallic foreign bodies; Intracranial aneurysm clips; Cardiac pacemakers and defibrillators; Cochlear implants; People with a significant head tremor; People with potential metal foreign bodies due to previous accidents (...) strong magnetic fields and radio frequency signals to generate metabolic, anatomical and functional brain images (fMRI). Remifentanil is a potent analgesic agent whose analgesic effect has been well characterised in healthy volunteers, including fMRI studies showing modulation of activation of regions in the brain related to pain processing. Nevertheless, the neural correlates of remifentanil effects have not yet been investigated in chronic pain patients. The aim of this research is to use

2014 Clinical Trials

5405. Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation

, aneurysm, intracranial or spinal surgery) severe uncontrolled arterial hypertension (hypertension defined as blood pressure 180/110 mm Hg (systolic BP > 180 mm Hg and/or diastolic BP > 100 mm Hg) on one single reliable measurement during current admission prior to study enrolment major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current AMI), recent trauma to the head or cranium prolonged or traumatic (...) related topics: available for: Groups and Cohorts Go to Group/Cohort Intervention/treatment METALYSE® Drug: METALYSE® weight-adjusted dosage as single bolus over 5 to 10 seconds Outcome Measures Go to Primary Outcome Measures : Number of serious adverse events (SAE) [ Time Frame: up to 30 days ] Secondary Outcome Measures : In-hospital rate of death [ Time Frame: up to 30 days ] In-hospital rate of stroke [ Time Frame: up to 30 days ] In-hospital rate of intracranial hemorrhage [ Time Frame: up to 30

2014 Clinical Trials

5406. The WEB-IT Clinical Study

Verified: October 2018 Keywords provided by Sequent Medical, Inc: Aneurysm Intracranial Aneurysm Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Additional relevant MeSH terms: Layout table for MeSH terms Aneurysm Intracranial Aneurysm Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases (...) . Patients with wide neck bifurcation aneurysms (WNBAs) have few choices for safe and effective endovascular treatment. In this study, all patients with qualifying WNBAs will be treated with the WEB. The primary effectiveness outcome of the study is the likelihood of complete intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory. Condition or disease Intervention/treatment Phase Wide Neck Bifurcation Intracranial Aneurysms Intracranial Aneurysms Device: WEB

2014 Clinical Trials

5407. Study on the Effect of Surgical Intestinal Manipulation

cases - blood sampling controles - blood sampling abdominal aortic aneurysm repair controls - blood sampling Other: blood sampling cases - blood sampling controles - blood sampling Outcome Measures Go to Primary Outcome Measures : subtypes of monocytes [ Time Frame: 1 day ] evaluate different subtypes of monocytes in brain-death donors by collecting portal and peripheral blood after lapaotomy and before dissection evaluate effect of intestinal manipulation [ Time Frame: 1 day ] evaluate the effect (...) information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: patients who are brain death patients who undergo an elective abdominal aortic aneurysm repair Exclusion Criteria: < 18 years of age Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2014 Clinical Trials

5408. Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study

converting to Alzheimer's Dementia. Repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive tool, has been recently approved for treatment of refractory depression. Since dysfunction in the frontal lobe of the brain is seen in patients with apathy, rTMS to the frontal lobe might be helpful in treating the same. Study hypotheses include that rTMS to the dorsolateral prefrontal cortex (DLPFC) will improve apathy and executive function better than sham treatment in those with MCI Condition (...) for treatment of refractory depression. Since dysfunction in the frontal lobe of the brain is seen in patients with apathy, rTMS to the frontal lobe might be helpful in treating the same. Specific Aims: To determine the efficacy of rTMS to the dorsolateral prefrontal cortex (DLPFC) in treating apathy in MCI in comparison to sham treatment. To compare the efficacy of rTMS to the DLPFC on executive function in MCI in comparison to sham treatment. Research Plan: Current study is a randomized sham controlled

2014 Clinical Trials

5409. Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia

Information provided by (Responsible Party): Prasad R. Padala, Central Arkansas Veterans Healthcare System Study Details Study Description Go to Brief Summary: Alzheimer's Dementia (AD) is a major public health problem. Apathy, a profound loss of motivation, is seen in majority of patients with AD. Dysfunction of the front of the brain and loss of dopamine, a type of neurochemical, in this part of brain results in apathy. Presence of apathy is linked to deficits in planning sequential tasks (...) such as keeping a routine. Patients with apathy have poor physical function and their caregivers experience extra burden. Unfortunately there are no good medications to treat apathy. FDA has approved the use of brain stimulation by a magnet known as repetitive transcranial magnetic stimulation (rTMS), for treatment of depression. rTMS increases dopamine when applied to frontal lobe of brain so we propose that rTMS would be a good treatment option for apathy in AD. Study hypotheses include that rTMS

2014 Clinical Trials

5410. A Phase III Long-term Study of TAK-536TCH in Patients With Essential Hypertension

working during the night. The participant has sleep apnea syndrome requiring treatment. The participant has any of the following cardiovascular diseases: Cardiac disease: Myocardial infarction*, coronary arterial revascularization*, severe valvular disorder, atrial fibrillation, any of the following conditions requiring treatment: angina pectoris, congestive heart failure, arrhythmia Cerebrovascular disorders: Cerebral infarction/cerebral hemorrhage*, transient ischemic attack* Vascular disease (...) : Peripheral artery disease with intermittent claudication, artery dissection, aneurysm Advanced hypertensive retinopathy: With bleeding or exudate/papilledema** * Occurring or performed within 24 weeks of the start of the run-in period ** Observed within 24 weeks of the start of the run-in period The participant has a clinically apparent hepatic disorder (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at Week -2 of the run-in period ≥ 2.5 times the upper limit of normal (ULN

2014 Clinical Trials

5411. Perioperative Neuroprotection of Stellate Ganglion Block

Hospital of Ningxia Medical University Information provided by (Responsible Party): General Hospital of Ningxia Medical University Study Details Study Description Go to Brief Summary: To investigate whether stellate ganglion block is helpful to brain protection during cranial aneurysm surgery Condition or disease Intervention/treatment Phase Intracranial Aneurysm Drug: Stellate Ganglion Block Not Applicable Detailed Description: The vasospasm after cranial aneurysm surgery have a higher incidence (...) table for MeSH terms Aneurysm Intracranial Aneurysm Ganglion Cysts Vasospasm, Intracranial Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Cysts Neoplasms Mucinoses Connective Tissue Diseases Ropivacaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents

2014 Clinical Trials

5412. Oxytocin Effects on Food Motivation Pathways

Description Go to Brief Summary: Oxytocin is a peptide hormone produced in the brain that regulates food intake. However, the mechanisms for this effect in humans is not yet clear. In this study, the investigators will therefore examine the effect of a single dose of intranasal oxytocin (compared to placebo) on levels of appetite-regulating hormones and functional magnetic resonance imaging activation of areas of the brain involved in food motivation. Condition or disease Intervention/treatment Phase (...) Date : May 2015 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Oxytocin Oxytocin 24 IU x 1 Drug: Oxytocin Single dose, intranasal Other Name: Syntocinon Placebo Comparator: Placebo Placebo 24 IU x 1 Drug: Placebo Single dose, intranasal Outcome Measures Go to Primary Outcome Measures : Change in functional magnetic resonance imaging activation of food motivation brain regions [ Time Frame: Functional

2014 Clinical Trials

5413. Dopamine Rhythms in Health and Addiction

will exclude. Presence of ferromagnetic objects in the body that are contraindicated for MRI of the head (pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments) or fear of enclosed spaces - self-report checklist. Personal or family history for cerebral aneurism. Past or present history of chest pain and trouble breathing with activity. Diabetes as assessed (...) on Alcohol Abuse and Alcoholism (NIAAA) ) Study Details Study Description Go to Brief Summary: Background: - Dopamine is a chemical signal linked to the rewarding effects of drugs. Certain genes make these effects sensitive to the time of day they are taken. Cocaine can affect these genes in the brain. Researchers want to measure brain dopamine at different times of day. Objectives: - To look for changes to a person s biological clock in the function of the dopamine reward system. To test if cocaine

2014 Clinical Trials

5414. A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder

, arrhythmias, congestive heart failure, angina), pulmonary, hepatic, renal, or endocrine disorders, which would increase the risk to the participant or interfere with interpretation of results as judged by the principal investigator. Clinically significant neurologic disease including, but not limited to, seizure disorder, neurodegenerative diseases, transient ischemic attacks, neural vascular disease, stroke, cerebral aneurysms, and history of traumatic brain injury. Female participants with a positive (...) and other procedures) but ketamine has not been approved by the FDA as a treatment for OCD. The investigators believe that ketamine may be effective in reducing symptoms of OCD due to its ability to decrease the activity of a specific brain chemical called glutamate. Previous studies have shown that people with OCD can have abnormal levels of glutamate in their brains. This is the first time that intranasal ketamine is being studied in people with OCD. However, studies have been done in the past using

2014 Clinical Trials

5415. Prospective, Non-randomized Multi-center, Controlled Physician-initiated Trial: Rotarex Belgium In-stent Occlusion

prior to enrolment Aneurysm in the target vessel Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol Major distal amputation (above the transmetatarsal) in the study limb or non-study limb Septicemia or bacteremia Any previously known coagulation disorder, including hypercoagulability Contraindication to anticoagulation or antiplatelet therapy Patient with known (...) hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II Currently participating in another clinical research trial The patient must be excluded in case any of the following contraindications as listed in the IFU is present: Rotarex®S catheters must not be used in case of: Patient not suitable for thrombectomy Target vessel belonging to the vessels of the cardiopulmonary, coronary or cerebral circulations Use inside or via

2014 Clinical Trials

5416. The Influence of tDCS on the Arm and Hand Function in Stroke Patients

> 6 months First ever stroke Decreased hand and arm function Mini Mental State Examination (>24) Exclusion Criteria: Depression Pregnancy Alcohol abuse Aneurysm clips Pacemaker Neurostimulator Implemented defibrillator Magnetically activated implant or device implemented pump Spinal cord simulator Implemented hearing aid Artificial or prosthetic limb Metal parts in the body Any external or internal metal Artificial heart valve Other implants History of brain surgery Migraine Family history (...) : Xue Zhang +3216376454 Sponsors and Collaborators Universitaire Ziekenhuizen Leuven More Information Go to Layout table for additonal information Responsible Party: Universitaire Ziekenhuizen Leuven ClinicalTrials.gov Identifier: Other Study ID Numbers: S54797 First Posted: August 6, 2014 Last Update Posted: August 6, 2014 Last Verified: February 2013 Additional relevant MeSH terms: Layout table for MeSH terms Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous

2014 Clinical Trials

5417. Safety Evaluation of 3K3A-APC in Ischemic Stroke

puncture time < 6 hours Exclusion Criteria: History of stroke or penetrating head injury within 90 days prior to enrollment History of previous or current diagnosis of intracranial hemorrhage that represents a potential for re-hemorrhage if subjected to thrombolytic therapy or mechanical thrombectomy Moyamoya disease, cerebral arterio-venous malformation (AVM), known unsecured aneurysm requiring intervention during the acute study period Presence of other neurological or non-neurological co-morbidities (...) Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by ZZ Biotech, LLC: ischemic stroke stroke APC 3K3A 3K3A-APC activated protein C RHAPSODY Additional relevant MeSH terms: Layout table for MeSH terms Stroke Ischemia Cerebral Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases

2014 Clinical Trials

5418. OCT Study of the MGuard Prime Stent in Patients With Heart Attacks

6 months, or any permanent neurologic deficit Prior intracranial bleed at any time, or known intracranial pathology (e.g. tumor, arteriovenous malformation, or aneurysm). Active or recent major bleeding within 6 months. History of bleeding diathesis or coagulopathy or inability to accept blood transfusions. Known hypersensitivity or contraindication to i) aspirin; or ii) heparin and bivalirudin; or iii) clopidogrel, prasugrel and ticagrelor; or iv) cobalt or nickel; or v) contrast media, which

2014 Clinical Trials

5419. Psychosis and Affective Research Domains and Intermediate Phenotypes

., artificial joints, brain aneurism clips, surgical pins, rods, wires, implants) or non-medical (e.g., metal piercing) irremovable metallic objects on/inside body (due to MRI-relevant risks) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02218853 (...) ('classical' endophenotypes). We then estimated the number of subgroups that efficiently optimized variance among the biomarkers (n=3) and differentiated the individual psychosis cases into these subgroups. Subsequently, the subgroups were tested for biological uniqueness using meaningful external validators (structural and functional brain imaging, social functioning, and familial data). Given the neurobiological distinctiveness of these subgroups, we called them psychosis Biotypes. DSM diagnoses were

2014 Clinical Trials

5420. Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

, traumatic brain injury, substance abuse, malignancy Clinically significant laboratory or ECG abnormality MRI indicative of any other significant abnormality, including but not limited to evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space occupying lesions Any condition that would contraindicate an MRI such as the presence of metallic objects in the eyes, skin, heart, or body Contacts and Locations Go to Information from the National Library (...) Collaborator: National Institute on Aging (NIA) Information provided by (Responsible Party): Roberta Brinton, University of Southern California Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants. The primary goal is to determine the maximally tolerated dose. Condition or disease Intervention/treatment Phase

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>